Boehringer has infringed 74 Humira patents, claims AbbVie
03-08-2017
360b / Shutterstock.com
A US judge has ordered Boehringer Ingelheim to release its rollout plans for a biosimilar version of Humira (adalimumab), following a request from AbbVie.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, patent, patent infringement, Boehringer Ingelheim, Humira, BPCIA, biologics, arthritis, biosimilars
